This inventor holds 1 USPTO granted patent. Top assignee: Thomas Jefferson University. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Christoph Wirblich: Innovator in COVID-19 Vaccine Development
Introduction
Christoph Wirblich is a notable inventor based in Wernau, Germany. He has made significant contributions to the field of vaccine development, particularly in response to the COVID-19 pandemic. His innovative work has the potential to impact public health on a global scale.
Latest Patents
Christoph Wirblich holds a patent for a vaccine targeting the Coronavirus disease (COVID-19). This invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or a portion thereof, along with methods of use. This patent represents a crucial step in the fight against COVID-19 and showcases his commitment to advancing medical science.
Career Highlights
Wirblich is affiliated with Thomas Jefferson University, where he continues to engage in groundbreaking research. His work at the university allows him to collaborate with other experts in the field, further enhancing the impact of his inventions.
Collaborations
Some of Christoph Wirblich's notable coworkers include Matthias Johannes Schnell and Drishya Kurup. Their collaborative efforts contribute to the advancement of vaccine research and development.
Conclusion
Christoph Wirblich's contributions to the field of vaccine development, particularly in relation to COVID-19, highlight his role as an important inventor in modern science. His work not only reflects his expertise but also his dedication to improving global health outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile